Drug Research
REGENXBIO Announces Orphan Drug Designation Granted to RGX-202, a Novel Gene Therapy Candidate for the Treatment of Duchenne Muscular Dystrophy
REGENXBIO Inc. announced the U.S. FDA granted Orphan Drug Designation for RGX-202, a potential one-time gene therapy for the treatment of Duchenne muscular dystrophy...
Drug Research
Chiesi Group focuses on biological drugs: an investment of 85 million euros for an international centre of excellence in Parma
Chiesi, the international research-focused pharmaceuticals and healthcare Group (Chiesi Group), presented today to the Italian Minister of Economic Development Giancarlo Giorgetti in Rome, the...
News
EC grants marketing authorisation to GSK-Virs Xevudy for Covid-19
The European Commission (EC) has granted marketing authorisation to GlaxoSmithKline (GSK) and Vir Biotechnology’s Xevudy (sotrovimab) to treat Covid-19 in the early stage.
The therapy...
Press Releases
SAB Biotherapeutics Announces SAB-185 Retains Neutralization Against Omicron SARS-CoV-2 Variant In Vitro
SAB Biotherapeutics , a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human polyclonal antibodies without the need for...
Packaging & Labelling
CSafe Global Announces Acquisition of Softbox Systems to Create the Global Leader in Temperature-Controlled Shipping Solutions
CSafe Global, the leader in temperature-controlled container solutions for the pharmaceutical industry, announced that it has acquired Softbox Systems, a provider of passive temperature-controlled...
Drug Research
ViiV Healthcare announces US FDA approval of Apretude, the first and only long-acting injectable option for HIV prevention
ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline plc (GSK), with Pfizer Inc. (Pfizer) and Shionogi Limited (Shionogi) as shareholders, announced...
Press Releases
Novavax and Serum Institute of India Announce WHO Emergency Use Listing for NVX-CoV2373 COVID-19 Vaccine
Novavax, Inc., a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, and Serum Institute of India Pvt. Ltd. (SII),...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from up to 5 devices at once
Must read